It was reported on May 21 that according to documents disclosed by the Hong Kong Stock Exchange on May 21, Liu Xinxin increased his off-market holdings at an average price of 136.21 yuan per share (RMB, same unit) on May 8$SKB BIO-B (06990.HK)$4.423,900 other shares, worth about 603 million yuan. After the increase in holdings, Liu Xinxin's latest shareholding was 83.2017 million shares, and the good position ratio increased from 85.10% to 85.78%.
Additional information: According to the targeted share subscription agreement signed between Colon Pharmaceuticals and Colun Botai, Colon Pharmaceuticals plans to subscribe for 4,423,870 shares of Colon Pharmaceuticals. The number and share of Colon Pharmaceuticals H shares held by Mr. Liu Gexin through the controlled corporation Colon Pharmaceutical will increase accordingly. The subscription is subject to review and approval by Colunbotai's shareholders' meeting and the completion of effective conditions such as registration with the China Securities Regulatory Commission. For box 26, the percentages are calculated by reference to the total number of unlisted shares after the subscription has been completed (i.e. 96,994,964).What is disclosure of interests?
As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. The directors and top executives of a listed company must disclose their interest in shares and debentures of the listed company and the company linked to the listed company.
Why is disclosure of interests important?
Disclosure of interests allows investors to identify (1) persons who control or are capable of controlling the stock interests of listed companies, and (2) persons who may benefit from transactions involving linked entities of listed companies.